Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management
Authors:
Open Access
- 20 October 2022
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 98 (1) , 193-209
Abstract
Disease Overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐Adapted Therapy: TNMB (tumor, node, metastasis, blood) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral or the blood involvement are generally approached with systemic therapies, including biologic‐response modifiers, histone deacetylase inhibitors, or antibody‐based strategies, in an escalating fashion. In highly‐selected patients, allogeneic stem‐cell transplantation may be considered, as this may be curative in some patients.Keywords
Funding Information
- National Institutes of Health (R37CA233476)
- National Institutes of Health (R01CA236722)
This publication has 285 references indexed in Scilit:
- Topical Chemotherapy in Cutaneous T-cell LymphomaJAMA Dermatology, 2013
- Single agent and combination studies of pralatrexate and molecular correlates of sensitivityBritish Journal of Cancer, 2010
- Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapyBlood, 2010
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapyProceedings of the National Academy of Sciences, 2010
- Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitorsBritish Journal of Haematology, 2009
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Acetylation Is Indispensable for p53 ActivationCell, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006